Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK's experimental herpes vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
FiercePharma
12d
As Sandoz contract winds down, GSK will close antibiotics plant in UK
With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...
2minutemedicine.com
5d
GSK: Depemokimab Monoclonal Antibody Reduces Asthma Attacks
Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...
FierceBiotech
12d
GSK's long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes
GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...
FiercePharma
7d
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...
STAT
10d
Pharmalittle: We’re reading about a Novo weight loss study, a GSK vaccine failure, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...
GlobalData on MSN
3d
MHLW accepts GSK’s multiple myeloma treatment NDA for review
Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.
2d
GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
World Trademark Review
2h
Video game filing trends; Supreme Court amicus warnings; Brand Action, GSK, Harley-Davidson, Mattel; and much more
Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.
3d
GSK settles two Zantac cases in California
GSK announced on Wednesday that it has reached confidential settlements in two lawsuits filed in California State Court ...
MM&M
9d
Rx Rundown: Summit Therapeutics, GSK, Bain Capital Life Sciences and more
DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...
FiercePharma
4d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since
GSK
’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback